Description:
Afatinib-[d6] is the labelled analogue of Afatinib. Afatinib is a medication approved for the treatment of metastatic non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It acts via inhibiting EGFR and HER2.
- Molecular Weight:491.98
- Purity:97%; ≥99% atom D
Molecular Formula:
C24H19D6ClFN5O3
Canonical SMILES:
CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4
InChI:
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1/i1D3,2D3
InChIKey:
ULXXDDBFHOBEHA-VCXSEIMGSA-N
Solubility:
Soluble in DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
Appearance:
White to Pale Yellow Solid
Storage: Store at -20°C
Synonyms:
Afatinib-d6; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide-d6; BIBW 2992-d6; Tovok-d6; Tomtovok-d6 Weitere Informationen finden Sie
hier